Bicycle Therapeutics reports Q3 net loss $28.3M; cash $361.5M; clinical pipeline progressing

BICYCLE THERAPEUTICS PLC

2022-Q3 EPS reported -$2.79 revenue$11,278,000

Net loss of $28.3M ($0.96 per share) vs $14.7M ($0.59) in Q3 2021.
Cash and equivalents $361.5M at Sep 30, 2022 ($438.7M Dec 31, 2021); runway into 2025.
R&D expenses $22.8M (up from $10.5M) driven by BT5528, BT8009, and platform costs.
Received $10M option fee from Genentech for expansion of immuno-oncology collaboration.
BT5528 showed 22% ORR in ovarian, 67% in urothelial; expansion enrollment on track for Q4 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.99

BICYCLE THERAPEUTICS PLC reported the third quarter ended September 30, 2022 results: net income Net loss was $28.3 million, or $(0.96) basic and diluted net loss per share, EPS $(0.96) basic and diluted net loss per share.

Period: the third quarter ended September 30, 2022
Net income: Net loss was $28.3 million, or $(0.96) basic and diluted net loss per share
EPS: $(0.96) basic and diluted net loss per share
Result: reported results

Exact text from the filing

Bicycle Therapeutics plc (the "Company") issued a press release announcing financial results for the fiscal quarter ended September 30, 2022

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

BICYCLE THERAPEUTICS PLC filing history →

Source: SEC EDGAR

accession 0001104659-22-114205

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.